Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22993267 | 0.84 | CYP2C19 (0.43) | MAPTCDK4CDK2CDK6MEN1 | |
| SCHEMBL16624078 | 0.78 | MAPT (0.40) | MAPTSMN1; SMN2HRH3CDK4CDK2 | |
| SCHEMBL20203493 | 0.77 | MAPT (0.38) | MAPTSMN1; SMN2HRH3CDK4CDK2 | |
| SCHEMBL16624105 | 0.77 | ASIC3 (0.39) | MAPTSMN1; SMN2HRH3CDK4CDK2 | |
| SCHEMBL26866988 | 0.77 | PIK3R1 (0.32) | MAPTMCHR1 | |
| SCHEMBL26866987 | 0.77 | PIK3R1 (0.34) | MAPTMCHR1 | |
| SCHEMBL22723932 | 0.77 | CYP3A4 (0.37) | MAPTHRH3GRM5 | |
| SCHEMBL18806115 | 0.75 | MAPT (0.36) | MAPTSMN1; SMN2HRH3CDK4CDK2 | |
| SCHEMBL24253486 | 0.75 | MAOA (0.40) | HRH3 | |
| SCHEMBL16624106 | 0.75 | PDCD1 (0.41) | MAPTSMN1; SMN2HRH3CDK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179511-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20200055948-A1 | CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055948-A1 | CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | BACE1, BACE2, GSAP | MAPT 1286/4885SMN1; SMN2 2609/4885HRH3 3104/4885 |
| US-20200179511-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | BACE1, BACE2, GSAP | MAPT 545/4885SMN1; SMN2 2905/4885HRH3 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.